Oncology
Edotreotide Improves PFS in GEP Neuroendocrine Tumors
In a phase 3 head-to-head trial, [177Lu]Lu-edotreotide extended progression-free survival compared with everolimus in progressive, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Rayan Salih · October 23, 2026 · 6 min